Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZTL-106 for chronic pain after knee or hip musculoskeletal injury
ACTRN12622000120774Phase 2Withdrawn
- Sponsor
- Levin Health
- Start
- May 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabis oil in chronic pain and Chronic non-cancer pain (CNCP), sponsored by Levin Health. Primary endpoints: Safety and tolerability of ZTL-106 and Pain interference with daily functions. Planned start May 2022; status: withdrawn.
02
Drugs
cannabis oil
03
Conditions
chronic painChronic non-cancer pain (CNCP)
Beyond the preview
Go deeper on ACTRN12622000120774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000120774.